Talk to an expert

Tell us what you need and we will call you back.

🇮🇳 +91

    Stock Audit · Pharmaceutical manufacturing

    Stock Audit for Pharmaceutical Manufacturers in India

    An independent count and valuation of a drug manufacturer's active ingredients, excipients, packing material, batches in process and finished products, compared with the books and, where the stock secures a loan, with the bank's stock statement. In a pharmaceutical plant every unit belongs to a batch with a quality status and a date, and much of the stock sits in controlled areas, so the count follows the site's own procedures and values each batch by what it can still be used or sold for.

    • 7+ years in practice (since 2019)
    • Reports reviewed and signed off by a Chartered Accountant
    Stock Audit for Pharma Manufacturing: Pharma stock, batch by batch.
    Pharma stock audit at a glance What is counted, where, and who asks for it
    Starting from ₹2,499 Exl GST and Govt. Charges · one unit, standard scope · travel quoted per location
    Final fee after scoping
    • What is counted Every batch of material and product, with its quality status (quarantined, under test, released, rejected) and its expiry or retest date
    • Where the stock sits Stores, controlled and cold-storage areas, production, finished goods stores and, where in scope, loan-licence or third-party sites
    • Who asks for it Your bank through the sanction letter; management, the statutory auditor or an investor when expiry write-offs rise or before a transaction
    • Where we count Anywhere in India, through local field teams coordinated by Patron; planning, scope and quality review stay with Patron
    The stock audit itself, its rules, procedure, report format and general records list are described once on the national stock audit page, linked under "Read here, read there" below.

    In short

    A pharmaceutical stock audit, in short

    Whoever orders it, a stock audit asks whether the stock in the books exists, belongs to you, can still be used or sold and is valued correctly. In a pharmaceutical plant the answer turns on more than quantity: the same drum of material is usable or unusable depending on a quality decision, much of the value sits in small weights of costly active ingredients, and the count team can enter some areas only under the site's gowning and access rules.

    This page covers what the industry changes: counting by batch and quality status, expiry and retest dates, quarantine, cold-chain items and controlled substances, the records a plant keeps, what the count usually finds and what moves the fee. The stock audit itself is described once on our India-wide stock audit page and is not repeated here.

    Read here, read there

    • Here
      What pharma stock changes in the count Batch and status, dates, controlled areas, cold chain, NDPS registers
    • Here
      Batch, expiry, quarantine and temperature excursions What the count records, and what it leaves to quality
    • Here
      Records, findings and fee drivers for pharma Release records, batch records, registers; the usual gaps; what moves the cost
    • National
      What a stock audit is, and when it is needed Meaning, who can sign, RBI's position
    • National
      How a stock audit is carried out The nine steps, full, test and cycle counts, cut-off, drawing power
    • National
      What the report contains The standard parts of a bank stock audit report
    • National
      Records to keep ready The general checklist, with the reason for each record

    What changes

    What makes pharmaceutical manufacturing stock different to audit

    Six things a count inside a drug plant has to respect that a count in an ordinary store never meets.

    Batch and status control

    Every material and product is tracked by batch, and only released batches may be used or sold. Quarantined, under-test, rejected and expired stock is physically present but not usable, so quantity alone says little.

    Regulated premises

    Manufacturing active ingredients needs a licence from the state licensing authority, and the site must meet Schedule M good manufacturing practice under the Drugs and Cosmetics Rules, 1945. Access, gowning and segregation rules bind the count team too.

    Expiry and retest dates

    Finished products expire, and many raw materials carry a retest date instead. Stock past either date loses value or cannot be used until it is tested again.

    Cold-chain items

    Some materials and products must stay within a temperature range, so they cannot wait outside their storage while a count team works through a rack line by line.

    Controlled substances

    Some materials fall under the Narcotic Drugs and Psychotropic Substances Act and are kept in statutory registers of their own, apart from the general stock records.

    Small weights, large values

    Active ingredients can cost many times more than the excipients around them, so a weighing difference of a few kilograms on one batch can matter more than a whole rack of packing material.

    Who asks for a pharma stock audit

    • Banks, where materials and finished products secure a working capital limit. No statute orders a borrower to have a stock audit; the requirement comes through the bank's sanction letter, and its frequency, commonly quarterly or half-yearly, is set there.
    • Management, the statutory auditor and investors, at year-end, during due diligence, or when write-offs for expiry and rejection rise.
    • Loan licensees and principals whose products are made at a third-party site and who want their stock there confirmed.

    A lender's stock audit covers one asset class, is commissioned by a lender rather than required by the Companies Act, reports to that lender and gives no opinion on the accounts. Most bank panels require a practising Chartered Accountant firm; some lenders also empanel Cost Accountants, so check your bank's panel conditions. Who may sign, and RBI's position, are under when a stock audit is needed on our India-wide stock audit page.

    Scope

    What a pharmaceutical manufacturing stock audit covers

    Every class of stock, batch by batch, with the status and the date that decide its value. The standard parts of a bank stock audit report are under what the stock audit report contains on our India-wide stock audit page.

    Stock category What is checked
    Active ingredients and excipients Quantity by batch, quality status (quarantine, approved, rejected) and retest date
    Packing material Quantity by item and version; printed material for discontinued artwork listed apart
    Work in progress Batches in process, by stage, checked against their batch records
    Finished products Quantity by product and batch, with status, expiry date and storage condition
    Rejected, returned and expired stock Kept apart from usable stock and valued separately
    Controlled substances Checked against their statutory register
    Stock at loan-licence or third-party sites Confirmed by statement or by a visit, as the scope says
    Valuation Lower of cost and net realisable value, with write-downs for near-expiry, expired and rejected stock

    What the report adds for pharma stock

    • Stock by status: released, quarantined, under test, rejected, expired and returned, each on its own line
    • Batch reconciliation: differences by batch, from receipt or manufacture to dispatch, with the explanation for each
    • Shelf life and retest: stock by remaining shelf life, and material past its retest date
    • Controlled substances: agreement between the statutory registers and the stock counted
    • Write-downs for expired, near-expiry, rejected and obsolete packing stock, and their effect on eligible stock

    Schedule M of the Drugs Rules 1945 governs storage and segregation; quarantined, rejected and returned material must be physically segregated and clearly labelled, which is what makes a count by status possible. Under AS 2 and Ind AS 2, inventory is carried at the lower of cost and net realisable value. The count records each batch's status as quality control has set it; it does not release, reject or test any batch.

    Sample with values hidden Sample stock audit report with all values hidden

    See a sample

    Stock audit report

    A summary of a stock audit report to the bank, with the stock and book-debt reconciliation and the drawing power.

    Prepared by
    A Chartered Accountant at Patron Accounting
    When you get it
    After the stock audit is completed.

    Values hidden for privacy. Names, numbers and dates are covered. Your own document carries your details.

    Download stock audit report sample (PDF) View stock audit report sample

    Process

    How the count runs in pharmaceutical manufacturing

    The method depends on the engagement scope and the site's own procedures: which areas the count team may enter, the gowning rules, how long cold-chain items may be handled, and whether production pauses. These are the steps pharma stock adds to the general stock audit procedure.

    1. 1
      Agree access with quality assurance

      Agree which areas will be counted and by whom, the gowning and hygiene rules, and how cold-chain and controlled items will be handled, before anyone enters a controlled area.

      You, quality assurance and the auditor
    2. 2
      Plan the cut-off

      Agree how dispensing, production issues, release and rejection decisions and dispatches during the count will be recorded, so that a batch changing status on the count day is counted once, in one status.

      You and the auditor
    3. 3
      Count by batch and status

      Count each batch where it sits, recording its status label and its expiry or retest date, and weigh or test-weigh active ingredients where the scope requires.

      Field team
    4. 4
      Handle cold-chain stock quickly

      Count temperature-controlled stock with the least time out of storage, or by label with a test count where the scope allows.

      Field team and your stores
    5. 5
      Reconcile controlled substances

      Count each controlled material on its own and compare it with the register entries written up to the cut-off, before it is added to the general count.

      Field team
    6. 6
      Test

      Where inventory is material, SA 501 expects the auditor to attend the physical count, evaluate management's procedures, inspect the inventory and perform test counts. Sample size and test checks are designed using the principles of SA 530 (Audit Sampling).

      Auditor
    7. 7
      Reconcile, value and report

      Reconcile with the stock and batch records, write down expired, near-expiry and rejected stock, recompute eligible stock where it secures a limit, discuss the differences with you and report. How long the report takes depends on the scope and the team needed, and is confirmed with your quote.

      Patron, to the bank

    The pharma task

    Batch, expiry, quarantine and temperature excursions

    The four things a pharma count records on every line that a general stock count does not, and the two kinds of stock that are reported on their own.

    Batch traceability

    A pharma count is reconciled batch by batch, not only in total: each batch's quantity should agree from receipt or manufacture through dispensing and yield to dispatch. For an active pharmaceutical ingredient, a small weighing difference on one batch can carry a large value.

    Expiry and stock rotation

    Pharmaceutical stores normally issue and dispatch the batch that expires first, known as FEFO. The count lists stock by remaining shelf life, writes near-expiry stock down to net realisable value and shows expired stock apart from saleable stock.

    Quarantine

    Under Schedule M good manufacturing practice, incoming materials are kept in quarantine until tested and released by quality control. Quarantine stock is physically present but not yet usable, so it is counted and shown as its own line, never as released stock.

    Retest dates

    Good manufacturing practice allows a retest date for stable active ingredients and raw materials; the material is retested then and used only if it still meets specification. Material past its retest date is not automatically worthless, but it is not counted as usable until retested.

    Temperature excursions and controlled substances: reported separately

    Where storage records show a temperature excursion, the affected batches may need quality review before they can be released or sold. The count identifies those batches from the temperature records and reports them separately; the decision on their quality stays with the site's quality unit.

    Controlled substances under the NDPS Act are checked against their statutory register and reconciled to physical stock separately. A difference there is a matter for the site's licence holder as well as for the valuation, so the report shows it on its own line rather than inside the general differences.

    What to keep ready

    Records the pharma count works from

    These are the records a drug plant keeps that a general stock audit does not ask for. The general list, sanction letter to insurance policy, is under records to keep ready before the count on our India-wide stock audit page.

    01
    Stock register by item, batch and location The book figure being tested, with status and dates for each batch
    02
    Quality control release, rejection and retest records To confirm each batch's status and the dates that decide its value
    03
    Batch manufacturing records To check work in progress, yields and dispensing differences
    04
    Statutory registers for controlled substances For the separate reconciliation of NDPS materials
    05
    Temperature records for controlled storage To identify batches affected by an excursion
    06
    Returns, recall and destruction records To explain stock that has left saleable inventory
    07
    Loan-licence and third-party site statements Where stock is made or held at another site
    08
    Bank sanction letter and stock statements Where the stock secures a limit: the scope, the margins and the figures already given to the bank

    Before the count team enters a controlled area

    • Confirm with quality assurance which areas will be counted, and by whom
    • Agree gowning, hygiene and escort arrangements for the count team
    • Print the batch list for each area with status, expiry and retest dates
    • Fix how long cold-chain items may stay out of storage during the count
    • Record every release and rejection decision made across the cut-off
    • Write up the controlled substances registers to the cut-off

    What the count finds

    What a pharma stock count usually finds

    The six differences that come up most often in a drug plant's stock, the usual reason, and what to change before the next count.

    Finding Usual cause What to do
    Rejected or quarantined stock valued as usable Status not updated in the stock records Link stock status to quality control release records
    Near-expiry finished goods at full value No review by remaining shelf life Review stock by remaining shelf life each month and write down
    Packing material for old artwork Artwork changed before old stock was used Count printed material at every artwork change
    Batch quantities that do not agree end to end Yield or dispensing differences not recorded Reconcile batch yields and investigate each difference
    Material past its retest date counted as usable Retest not scheduled Track retest dates and retest before use
    Controlled substance register not agreeing with stock Entries not made on the day of movement Write up the register at every movement and reconcile regularly

    Why expired and rejected stock matters to the bank, and to GST

    Many banks exclude obsolete, expired or slow-moving stock from drawing power, using ageing cut-offs set in their own policy and sanction letter, so rejected or expired batches carried at cost overstate the stock the limit rests on. Under section 17(5)(h) of the CGST Act, input tax credit must be reversed on goods lost, stolen, destroyed, written off, or given as gifts or free samples, so destroying expired batches and issuing physician samples carry a GST effect as well as a valuation one.

    Fees

    What drives the fee for a pharma count

    A written quote once the sites, the storage areas, the batches and the access rules are known. The general cost drivers of a stock audit are under what a stock audit costs on our India-wide stock audit page.

    Professional fee

    Get a quote Exl GST and Govt. Charges · final fee after scoping

    The quote follows the number of batches and the conditions the count must work under more than the value of the stock. travel quoted per location Work usually starts within 3 to 5 working days of confirmation.

    Fees exclude GST and government charges. All fees listed are indicative only and do not constitute a binding offer; the final amount is confirmed after a scoping review and depends on the volume of work and the complexity involved.

    What moves the fee in pharma

    • Sites and storage areas How many plants, stores and controlled areas hold the stock
    • Items and batches The number of batches to be counted with their status and dates
    • Access and gowning The time controlled areas take to enter and work in
    • Cold-chain and controlled stock How much stock needs quick handling or a separate register reconciliation
    • Third-party sites Whether loan-licence or contract sites are visited or confirmed by statement

    For a quote, send the number of sites, the number of items and batches, any cold-chain or controlled stock, and whether the stock secures a bank limit, and you will receive the fee and the records list in writing.

    How it is delivered

    Where we count, and who stands behind the report

    Patron Accounting runs stock audits across India through local field teams coordinated by Patron. Engagement planning, scope and quality review stay with Patron, and the report is reviewed and signed off by a Chartered Accountant.

    Stock audits since 2019 Stock audits of all kinds, since 2019.
    Plants and sites anywhere in India Counted by local field teams coordinated by Patron; planning, scope and quality review by Patron. Name the plants, stores and any third-party sites when you enquire.
    Reviewed and signed off by a CA Content reviewed by Subham Jhunjhunwala, CA Finalist; regulatory and banking statements signed off by CA Sundram Gupta.

    Sources used on this page

    • Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 (manufacturing licences; Schedule M good manufacturing practice)
    • Narcotic Drugs and Psychotropic Substances Act, 1985 (statutory registers for controlled substances)
    • CGST Act, 2017, section 17(5)(h) (credit reversal on goods destroyed, written off or given as free samples)
    • ICAI, Standards on Auditing SA 501 (attendance at physical inventory counting) and SA 530 (audit sampling)
    • Accounting Standards AS 2 and Ind AS 2 (inventories: lower of cost and net realisable value)
    • Reserve Bank of India directions and circulars on working capital finance, and the Companies (Auditor's Report) Order, 2020, for the lender's position and the line between a lender's stock audit and the statutory audit

    Statements about audit frequency, panels and ageing exclusions describe common bank practice; your own sanction letter decides how they apply to you.

    Read

    Guides and terms for a pharma stock count

    For the general audit

    The report format, the RBI position, how often a stock audit is required and the common deficiencies a bank stock audit finds are covered by the guides linked from the national stock audit page.

    Get a quote

    Ask for a pharma stock audit quote

    Share the number of sites, the number of items and batches, any cold-chain or controlled stock and whether the stock secures a bank limit, and you will receive a quote and a list of records to prepare.

    Get a quote for a pharma stock audit

    We reply on working days.

    🇮🇳 +91

      Stock that is not pharmaceutical, or a different service? Say so in the message and the right team calls instead. By sending this form you agree to our privacy policy. No spam, no sharing of your details.

      Prefer to chat?

      Message us on WhatsApp with the bank's request and your sites, and the stock audit team replies.

      Or call and write

      Working hours: Monday to Saturday, 9 AM to 6 PM.

      What happens next

      A CA reads the bank's request, confirms the sites, the areas and the access rules, and sends the scope, the fee and the records list in writing before any visit is planned.

      Get a quote for a pharma stock audit

      Tell us about the bank's request and your sites, and a CA calls you back.

      🇮🇳 +91

        By sending this form you agree to our privacy policy.